A computer-aided detection and localization system could fine-tune diagnosis of small hepatocellular carcinomas with multislice CT, according to a study presented at the European Congress of Radiology in March.
A computer-aided detection and localization system could fine-tune diagnosis of small hepatocellular carcinomas with multislice CT, according to a study presented at the European Congress of Radiology in March.
Features of some liver lesions may be hard to spot or characterize with contrast-enhanced MSCT studies. An automated, accurate localization of these lesions during multiple scanning phases could make the evaluation of their enhancement patterns and diagnosis more efficient.
Guo-Qing Wei, Ph.D., and colleagues at the research division of Siemens Medical Solutions proposed a computer application to detect small liver cancers during multiple-phase contrast-enhanced CT scanning. Using 35 studies from cancer patients as a reference, they devised a technique to isolate suspected liver lesions smaller than 30 mm from nonliver tissue. This technique accurately registered small hepatocellular carcinomas across MSCT liver scans.
Three imaging specialists marked 41 small lesions with a suspicious appearance by consensus. They used a segmentation technique to reconstruct a liver volume in each contrast phase. They then applied an intensity-weighting method to suppress nonliver anatomies and employed a cross-correlation technique to find corresponding slices across different phases.
The investigators obtained detection rates of 82.9%, 90.2%, and 78% between precontrast/arterial, arterial/portal venous, and across simultaneous phases, respectively. They recorded a mean registration error of 0.4 slices.
Physicians could use the proposed intensity-weighted cross-correlation method to develop efficient detection tools to bolster diagnosis of small hepatocellular carcinomas, the researchers said.
Wei's study adds an alternative approach to the findings of Dr. Yu-Len Huang, a radiologist at the China Medical University Hospital in Taichung, Taiwan. Huang and colleagues tried a computerized model that accurately characterizes benign from malignant liver tumors without the need for contrast agents, which could avoid renal toxicity and allergic reactions in certain patients (Mid Taiwan J Med 2004;9:141-150).
For more information from the Diagnostic Imaging archives:
Recent research developments address RFA of the liver
CAD acquisition parameters prove critical to accuracy
CAD falls within cost-effectiveness range
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.